clinical trial · NCT05613088
A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Bristol-Myers Squibb·phase2·completed·n = 106
Neoplasms, OvarianMORAb-202PaclitaxelPegylated Liposomal Doxorubicin (PLD)Topotecan
brief summary
The purpose of the study is to assess the safety, tolerability, and efficacy of farletuzumab ecteribulin (MORAb-202) and compare it to Investigator's choice (IC) chemotherapy in female participants with platinum-resistant HGS ovarian, primary peritoneal, or fallopian tube cancer.
started
Feb 1, 2023
primary completion
Jun 17, 2024
completion
Sep 10, 2025
last updated
Apr 30, 2026
official title
A Phase 2 Open-label Randomized Study of Farletuzumab Ecteribulin (MORAb-202), a Folate Receptor Alpha-targeting Antibody-drug Conjugate, Versus Investigator's Choice Chemotherapy in Women With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol